Low dose chloroquine decreases insulin resistance in human metabolic syndrome but does not reduce carotid intima-media thickness.
Janet B McGillMariko JohnsonStacy HurstWilliam T CadeKevin E YarasheskiRichard E OstlundKenneth B SchechtmanBabak RazaniMichael B KastanDonald A McClainLisa de Las FuentesVictor G Davila-RomanDaniel S OrySamuel A WicklineClay F SemenkovichPublished in: Diabetology & metabolic syndrome (2019)
These findings suggest that low dose chloroquine, which improves the metabolic syndrome through ATM-dependent mechanisms in mice, modestly improves components of the metabolic syndrome in humans but is unlikely to be clinically useful in this setting.Trial registration ClinicalTrials.gov (NCT00455325, NCT00455403), both posted 03 April 2007.
Keyphrases
- metabolic syndrome
- low dose
- insulin resistance
- cardiovascular risk factors
- uric acid
- high dose
- endothelial cells
- high fat diet induced
- clinical trial
- dna damage
- phase iii
- cardiovascular disease
- induced pluripotent stem cells
- type diabetes
- plasmodium falciparum
- skeletal muscle
- dna damage response
- pluripotent stem cells